• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[勃起功能障碍。流行病学、生理学、病因学、诊断与治疗]

[Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy].

作者信息

Derouet H, Osterhage J, Sittinger H

机构信息

Urologische Universitätsklinik, 66421 Homburg/Saar, Germany.

出版信息

Urologe A. 2004 Feb;43(2):197-207; quiz 208-9. doi: 10.1007/s00120-003-0527-9.

DOI:10.1007/s00120-003-0527-9
PMID:14991124
Abstract

Erectile dysfunction is a common, age-dependent functional disturbance of men associated to various comorbidities. Interdisciplinary cooperation with neurologists in cases of a suspected neurological aetiology and with psychiatrists in cases with normal organic diagnostic findings is necessary. Hormone replacement and psychotherapy can cure certain patients. Oral pharmacotherapy is the most effective therapy for erectile dysfunction with the highest patient preference. Oral PDE-5-inhibitors (sildenafil, tadalafil, vardenafil) are superior in effectiveness to centrally acting drugs (apomorphin, yohimbine). Local pharmacotherapy (MUSE, ICI) is a second line therapy in cases of failure or contraindications for oral pharmacotherapy. Vacuum therapy and operative procedures (penile implants) complete the therapeutic options of erectile dysfunction.

摘要

勃起功能障碍是一种常见的、与年龄相关的男性功能障碍,与多种合并症有关。对于疑似神经病因的病例,需与神经科医生进行跨学科合作;对于器质性诊断结果正常的病例,则需与精神科医生合作。激素替代疗法和心理治疗可以治愈某些患者。口服药物治疗是治疗勃起功能障碍最有效的方法,患者的接受度也最高。口服磷酸二酯酶-5抑制剂(西地那非、他达拉非、伐地那非)在疗效上优于中枢作用药物(阿扑吗啡、育亨宾)。局部药物治疗(尿道内给药、阴茎海绵体内注射)是口服药物治疗失败或有禁忌证时的二线治疗方法。真空疗法和手术治疗(阴茎植入)完善了勃起功能障碍的治疗选择。

相似文献

1
[Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy].[勃起功能障碍。流行病学、生理学、病因学、诊断与治疗]
Urologe A. 2004 Feb;43(2):197-207; quiz 208-9. doi: 10.1007/s00120-003-0527-9.
2
[Erectile function disorders. Epidemiology, physiology, etiology, diagnosis and therapy].[勃起功能障碍。流行病学、生理学、病因学、诊断与治疗]
Nervenarzt. 2004 Jun;75(6):595-605; quiz 606-7.
3
A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?勃起功能障碍治疗方案的比较性综述:何种治疗适用于何种患者?
Drugs. 2005;65(12):1621-50. doi: 10.2165/00003495-200565120-00003.
4
[Therapy for organic erectile dysfunction].[器质性勃起功能障碍的治疗]
Urologe A. 2005 Oct;44(10):1160-6. doi: 10.1007/s00120-005-0910-9.
5
Current treatments and emerging therapeutic approaches in male erectile dysfunction.
BJU Int. 2001 Oct;88 Suppl 3:11-7. doi: 10.1046/j.1464-4096.2001.123.x.
6
Patient education series. Erectile dysfunction.患者教育系列。勃起功能障碍。
Nursing. 2005 Feb;35(2):64. doi: 10.1097/00152193-200502000-00043.
7
Is vardenafil "noninferior" or superior to sildenafil in the management of erectile dysfunction? Revisiting the biochemical, physiological, and clinical evidence.在勃起功能障碍的治疗中,伐地那非比西地那非“非劣效”还是更具优势?重新审视生化、生理及临床证据。
J Sex Med. 2008 Jul;5(7):1762-8; discussion 1768-9. doi: 10.1111/j.1743-6109.2007.00719.x.
8
Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.耻骨后根治性前列腺切除术后勃起功能障碍:流行病学、病理生理学及药物治疗
Drugs Aging. 2006;23(2):101-17. doi: 10.2165/00002512-200623020-00002.
9
Therapy of ED: PDE-5 Inhibitors.
Endocrine. 2004 Mar-Apr;23(2-3):135-41. doi: 10.1385/ENDO:23:2-3:135.
10
There have been inadequate warnings that erectile dysfunction drugs can cause blindness.一直以来都存在警示不足的情况,即勃起功能障碍药物可能会导致失明。
MedGenMed. 2005 Dec 5;7(4):61.

引用本文的文献

1
[Quality assurance in the urologist's practice. Erectile dysfunction as an example of a multicenter approach to documenting treatment results].
Urologe A. 2005 Jul;44(7):785-93. doi: 10.1007/s00120-005-0837-1.

本文引用的文献

1
Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups.
Urology. 2003 Sep;62(3):519-23; discussion 523-4. doi: 10.1016/s0090-4295(03)00491-6.
2
Tolerability and safety of apomorphine SL (Ixense (TM) ).阿扑吗啡口腔崩解片(Ixense™)的耐受性与安全性。
Int J Impot Res. 2003 Apr;15 Suppl 2:S7-9. doi: 10.1038/sj.ijir.3900991.
3
Prevalence of erectile dysfunction in France: results of an epidemiological survey of a representative sample of 1004 men.
Eur Urol. 2002 Oct;42(4):382-9. doi: 10.1016/s0302-2838(02)00323-8.
4
Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.他达拉非治疗勃起功能障碍的疗效与安全性:综合分析结果
J Urol. 2002 Oct;168(4 Pt 1):1332-6. doi: 10.1016/S0022-5347(05)64442-4.
5
Is erectile dysfunction a marker for cardiovascular disease?
Int J Clin Pract. 2001 Nov;55(9):614-8.
6
Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.勃起功能障碍的流行病学:“科隆男性调查”结果
Int J Impot Res. 2000 Dec;12(6):305-11. doi: 10.1038/sj.ijir.3900622.
7
Brain control of penile erection.
World J Urol. 2001 Feb;19(1):1-8. doi: 10.1007/pl00007089.
8
Cross-regulation of intracellular cGMP and cAMP in cultured human corpus cavernosum smooth muscle cells.培养的人阴茎海绵体平滑肌细胞内cGMP和cAMP的交叉调节
Mol Cell Biol Res Commun. 2000 Jul;4(1):10-4. doi: 10.1006/mcbr.2000.0249.
9
Apomorphine: an update of clinical trial results.阿扑吗啡:临床试验结果的最新情况。
Int J Impot Res. 2000 Oct;12 Suppl 4:S67-73. doi: 10.1038/sj.ijir.3900581.
10
AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients.用于治疗勃起功能障碍的美国美敦力公司三件套可膨胀植入物:对200例患者的长期多机构研究
Eur Urol. 2000 Jan;37(1):50-5. doi: 10.1159/000020099.